An FDA panel reviewed a drug for Duchenne muscular dystrophy called drisaperson on Tuesday. What it found is not encouraging. The Signal podcast takes a look at what happened and where things go from here.

UPDATE: What happened at the FDA panel review of one Duchenne drug?

The impact of modern medicine on the human condition can’t be underestimated. From antibiotics to vaccines, medicine has changed the way our bodies work, answered deadly questions, and promised faster cures.
 
But it’s not simple. Drug development is rife with tension. It costs a lot of money, and takes a long time. Most things fail. But when they succeed, they can make a tremendous difference in people’s lives. 
 
Where will the next breakthroughs come from? How will we pay for them? Who decides who gets them? 
 
This is SIGNAL, a podcast from Stat that sorts through the flood of health and medical news to deliver stories of the next development, controversy or breakthrough that will affect us all. Hosted by veteran biotech journalist Luke Timmerman and CNBC biotech and pharma reporter Meg Tirrell, SIGNAL explores the characters and the dramas behind today’s medicine, from biotech boardrooms, to research labs, to your corner pharmacy. Subscribe to us on iTunes and Stitcher, or visit us on our website, www.statnews.com.

Science

The impact of modern medicine on the human condition can’t be underestimated. From antibiotics to vaccines, medicine has changed the way our bodies work, answered deadly questions, and promised faster cures. But it’s not simple. Drug development is rife with tension. It costs a lot of money, and takes a long time. Most things fail. But when they succeed, they can make a tremendous difference in people’s lives. Where will the next breakthroughs come from? How will we pay for them? Who decides who gets them? This is SIGNAL, a podcast from Stat that sorts through the flood of health and medical news to deliver stories of the next development, controversy or breakthrough that will affect us all. Hosted by veteran biotech journalist Luke Timmerman and CNBC biotech and pharma reporter Meg Tirrell, SIGNAL explores the characters and the dramas behind today’s medicine, from biotech boardrooms, to research labs, to your corner pharmacy. Subscribe to us on iTunes and Stitcher, or visit us on our website, www.statnews.com.

Share UPDATE: What happened at the FDA panel review of one Duchenne drug?

Sign up to save your podcasts

UPDATE: What happened at the FDA panel review of one Duchenne drug?

UPDATE: What happened at the FDA panel review of one Duchenne drug?